Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
New forces are joining in the battle against the new coronavirus outbreak. Regeneron Pharmaceuticals Inc.and the US Department of Health and Human Services (HHS) are expanding a collaboration to include 2019-nCoV, given that Regeneron’s REGN-EB3 has demonstrated effectiveness against the Ebola virus.
REGN-EB3, an combination therapy comprising three antibodies, has been granted US Breakthrough Therapy designation and Regeneron has filed a rolling Biologic License Application with the US FDA for Ebola. EB3 is the second potential therapeutic treatment for this virus after Ridgeback Biotherapeutics' monoclonal antibody mAb114, which also scored an expedited pathway for Ebola. A Phase II/III study for EB3 conducted in Congo was stopped early after the antibody met predetermined criteria.
Another drug investigated for Ebola, Gilead Sciences Inc.’s remdesivir, has gained expedited approval from China’s National Medical Products Administration for a Phase III study in the coronavirus, to be conducted at the Wuhan Sino-Japan Friendship Hospital and scheduled to commence as soon as the drug arrives. (Also see "Gilead Joins Coronavirus Fray With Repurposed Antiviral" - Scrip, 2 Feb, 2020.)
Patent Filing Questions
Although remdesivir is patented by Gilead, the Wuhan Institute of Pathology has applied for a patent in China for the new use. In its 21 January filing, the institute, which is under the China Academy of Science, said the patent would protect national interests and would use the Patent Collaboration Treaty to enter other markets worldwide.
On 4 February, the Wuhan institute published an article inCell Researchshowing that combining remdesivir with chloroquine shows efficacy on 2019-nCoV ex vivo; in-human efficacy is yet to be confirmed.
The new patent filing raises many questions about the timing. Just one day before this, on 20 January, China’s top respiratory expert, Zhong Nanshan, went public for the first time about human-to-human transmission of the new virus. The institute then filed the patent the following day, despite a lack of trials in people affected by 2019-nCoV.
Revised Treatment Guidelines
Meanwhile, China’s National Health Commission has released the fifth version of its coronavirus treatment guidelines, adding ribavirin to previously listed AbbVie Inc.’s repurposed antiviral Kaletra (lopinavir and ritonavir) plus nebulized alpha-interferon. The use of Kaletra, an anti-HIV treatment, has some experts in China questioning its efficacy against the new virus.
Local health authorities in Guangdong are also considering an emergency approval for Pneumonia No.1, a traditional Chinese medicine developed by a local hospital. In a real world study in which 50 patients with mild pneumonia were treated with the TCM, after one week all are said to have showed improvement, with body temperatures dropping to normal levels.
As of midnight on 4 February, confirmed cases had reached 24,324 in China, of which 3,219 were severe, with 490 deaths. Suspected cases seem to be stabilizing, standing at 23,260 compared to 23,214 reported the day before.
Scrip: industry news and insights, Datamonitor Healthcare: d...
In 2019, the 10 most lucrative medicines generated combined global sales of $92.5B. Scrip provides insight into these top sellers and the companies behind them, as well US dynamics, global sales forecasts and lifecycle data, with complementary market analysis from Datamonitor Healthcare on diseases targeted, indications, and more.
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
Biomedtracker: see the drug development process through analysts’ eyes
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.